title: Association between SLCO1B1 521 T＞C and 388 A＞G Polymorphisms and Statins Effectiveness: A Meta-Analysis.
abstract: OBJECTIVE
  Previous studies on the association between the SLCO1B1 521 T＞C and 388 A＞G polymorphisms and statin effectiveness have been inconsistent. We performed this meta-analysis to provide a more comprehensive estimation of this issue.
  
  
  METHODS
  Multiple electronic literatues databases were searched on March 5th 2014. A quality assessment was performed using the Methodological Index for Non-Randomized Studies (MINORS) criteria. A meta-analysis, sub-group analysis, sensitivity analysis (RevMan 5.2), publication bias measuring and meta-regression analysis were conducted utilizing the Stata software program (version 12.0).
  
  
  RESULTS
  A total of 13 studies were included in the final meta-analysis, which included 7,079 participants. Overall, there was no statistically significant association in the four genetic models of hypolipidemic effect. For the 521 T＞C polymorphism, significant associations were found for the long-term effectiveness of lowering the low-density lipoprotein cholesterol (LDL-C) and in non-Asian populations in the dominant model [(CC＋TC vs. TT: mean difference (MD)=1.44, 95% CI: 0.25-2.64,p=0.02) and (CC＋TC vs. TT: MD=1.38, 95% CI: 0.28-2.49, p=0.01)], the recessive model [(CC vs. TT＋TC: MD=3.31, 95% CI: 0.09-6.54, p=0.04) and (CC vs. TT＋TC: MD=2.83, 95% CI: 0.26-5.41, p=0.03)], and the homozygote comparison [(CC vs. TT: MD=3.68, 95% CI: 0.42-6.94,p=0.03) and (CC vs. TT: MD=3.33, 95% CI: 0.67-5.99, p=0.01)], respectively. There were no significant differences for the other analyses of the 521 T＞C polymorphism or all the analyses of the 388 A＞G polymorphism.
  
  
  CONCLUSIONS
  The overall results suggest that the SLCO1B1 521 T＞C and 388 A＞G polymorphisms do not affect the lipid-lowering effectiveness of statins. However, allele C of the SLCO1B1 521 T＞C polymorphism leads to an attenuated effect on lowering the LDL-C in non-Asian populations and the long-term effectiveness of statin treatment.
authors.affiliation: School of Public Health and Management, Research Center for Medicine and Social Development, The Innovation Center for Social Risk Government in Health.
authors.forename: Rong
authors.initials: R
authors.lastname: Dai
authors.forename: Jing
authors.initials: J
authors.lastname: Feng
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Yang
authors.forename: Changkai
authors.initials: C
authors.lastname: Deng
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Tang
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhao
authors.forename: Hao
authors.initials: H
authors.lastname: Zhou
authors.forename: Fan
authors.initials: F
authors.lastname: Zhang
mesh_terms: D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000235:genetics*; D027381:Liver-Specific Organic Anion Transporter 1; D027361:Organic Anion Transporters / Q000235:genetics*; D011110:Polymorphism, Genetic; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D027381:Liver-Specific Organic Anion Transporter 1; D027361:Organic Anion Transporters; C503999:SLCO1B1 protein, human